Eli Lilly & Co. (LLY) Releases FY13 Earnings Guidance
Eli Lilly & Co. (LLY) issued an update on its FY13 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $3.82-3.97 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.83. The company issued revenue guidance of $22.6-23.4 billion, compared to the consensus revenue estimate of $22.91 billion.
Shares of Eli Lilly & Co. (LLY) opened at 52.64 on Tuesday. Eli Lilly & Co. (LLY) has a one year low of $38.30 and a one year high of $53.99. The stock’s 50-day moving average is currently $50.93. The company has a market cap of $58.936 billion and a P/E ratio of 14.28.
Eli Lilly & Co. last issued its quarterly earnings data on Tuesday, January 29th. The company reported $0.85 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.82 by $0.03. The company had revenue of $5.96 billion for the quarter, compared to the consensus estimate of $5.78 billion. During the same quarter last year, the company posted $0.87 earnings per share. Eli Lilly & Co.’s revenue was down 1.5% compared to the same quarter last year. Eli Lilly & Co. has set its FY13 guidance at $3.82-3.97 EPS. Analysts expect that Eli Lilly & Co. (LLY) will post $3.33 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, March 8th. Shareholders of record on Friday, February 15th will be given a dividend of $0.49 per share. This represents a $1.96 dividend on an annualized basis and a yield of 3.72%. The ex-dividend date of this dividend is Wednesday, February 13th.
Several analysts have also recently commented on the stock. Analysts at Leerink Swann reiterated an outperform rating on shares of Eli Lilly & Co. in a research note to investors on Wednesday, January 23rd. On a related note, analysts at TheStreet reiterated a buy rating on shares of Eli Lilly & Co. in a research note to investors on Tuesday, January 22nd. Finally, analysts at JPMorgan Chase reiterated a neutral rating on shares of Eli Lilly & Co. in a research note to investors on Tuesday, January 22nd. They now have a $55.00 price target on the stock.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.